Dean Valentine, a 59-year-old grandfather from Essex, claims that his life was turned upside down after receiving the Pfizer Covid vaccine in December 2021. Prior to the vaccine, Valentine was a healthy and active individual who enjoyed golfing, holidays, and spending time with his family. However, shortly after receiving the vaccine, he began to experience “devastating” and “bizarre” symptoms, including intense dizziness, full body tremors, and a permanent headache.

Despite seeking medical attention and trying various treatments, including private healthcare and health retreats, Valentine’s symptoms have persisted. He estimates that he has spent around £100,000 trying to find a cure, but to no avail. Valentine’s condition has left him a “shadow of the man he was,” and he feels like he is only 10% of his former self.

Valentine is certain that his symptoms are a result of the Covid vaccine, and he has been told the same by various professors and specialists. He is not seeking compensation, but rather wants to raise awareness about the potential risks of the vaccine and push for a medical pathway to be created for people who are suffering from similar symptoms.

Valentine’s story is not an isolated incident, as thousands of people have reported experiencing adverse reactions to the Covid vaccine. Recent studies have linked the vaccine to chronic conditions, including a previously unknown condition known as “post-vaccination syndrome,” which can cause brain fog, dizziness, and exercise intolerance.

Pfizer has stated that patient safety is paramount and that they take all reports of adverse events seriously. However, the company also notes that adverse event reports do not imply causality and that the benefit-risk profile of the vaccine remains positive for all authorized indications and age groups.

Valentine’s case highlights the need for further research into the potential risks and side effects of the Covid vaccine. He has raised over £25,000 through charity events to help people struggling with similar symptoms and is calling for a medical pathway to be created to support those affected. Valentine’s story is a heartbreaking reminder of the importance of prioritizing patient safety and ensuring that those who have been affected by the vaccine receive the help and support they need.

Pfizer has secured global licensing rights, excluding China, for 3SBio’s dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a novel, dual-targeting antibody-drug conjugate (ADC) that has shown potential in treating various types of cancer.

Under the terms of the agreement, Pfizer will be responsible for the development, manufacture, and commercialization of SSGJ-707 worldwide, except in China, where 3SBio will retain the rights. 3SBio will receive an upfront payment, as well as potential milestone payments and royalties on future sales.

SSGJ-707 is designed to target two specific proteins, CD19 and CD22, which are commonly expressed in certain types of cancer, including B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. The dual-targeting approach is intended to improve the efficacy and safety of the treatment, as well as reduce the risk of resistance.

The ADC technology used in SSGJ-707 involves linking a cytotoxic drug to a monoclonal antibody, which is designed to selectively target and kill cancer cells. This approach has shown promise in treating a range of cancer types, including hematological malignancies and solid tumors.

Pfizer’s acquisition of the global licensing rights for SSGJ-707 outside of China is a strategic move to strengthen its oncology portfolio. The company has been actively expanding its presence in the cancer treatment market, with a focus on innovative therapies that can improve patient outcomes.

The partnership with 3SBio is expected to accelerate the development of SSGJ-707, with Pfizer’s global resources and expertise enabling the therapy to reach a broader patient population. 3SBio, on the other hand, will benefit from Pfizer’s commercialization capabilities, while retaining the rights to the therapy in China.

This collaboration highlights the growing trend of partnerships between pharmaceutical companies and biotech firms, as they seek to leverage each other’s strengths to bring innovative treatments to market. The deal also underscores the increasing importance of China as a major player in the global biopharmaceutical industry, with companies like 3SBio emerging as key partners for international pharmaceutical companies. Overall, the licensing agreement between Pfizer and 3SBio has the potential to bring a promising new cancer therapy to patients worldwide, and marks an important step forward in the fight against cancer.